Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
CMPI was delisted on the 27th of May, 2022.
34 hedge funds and large institutions have $97.3M invested in Checkmate Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 12 closing their positions.
8% less funds holding
Funds holding: 37 → 34 (-3)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
52% less capital invested
Capital invested by funds: $203M → $97.3M (-$105M)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$1.52M |
| 2 |
RC
RBF Capital
San Francisco,
California
|
+$487K |
| 3 |
Millennium Management
New York
|
+$286K |
| 4 |
E
Ergoteles
New York
|
+$187K |
| 5 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
+$177K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.44M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.01M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$987K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$446K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$354K |
CMPI Hedge Fund Activity: Q2 2021 in Review
34 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) for Q2 2021, worth a combined $97.3M — down 52% from $203M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CMPI and 9 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 4 added.
The largest buyer was Clough Capital Partners, adding an estimated $1.52M. The largest seller was BlackRock, cutting an estimated $2.44M.
- 34 institutional investors held Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) as of Q2 2021, down from 37 in Q1 2021.
- Funds reported $97.3M of Checkmate Pharmaceuticals, Inc. Common Stock stock for Q2 2021, down 52% quarter-over-quarter.
- 9 funds opened new Checkmate Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 12 closed out, a net change of -3 holders.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was Clough Capital Partners, an estimated $1.52M added.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was BlackRock, an estimated $2.44M sold.
Based on aggregated 13F filings for Q2 2021.